Cargando…
Chromatin signaling and neurological disorders /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London :
Academic Press,
[2019]
|
| Colección: | Translational epigenetics series ;
v. 12. |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Chromatin Signaling and Neurological Disorders; Translational Epigenetics Series; Chromatin Signaling and Neurological Disorders; Copyright; Contents; Contributors; Preface; Chromatin and epigenetics; Chromatin signaling and neurological diseases; References; 1
- Chromatin and epigenetic signaling pathways; 1.1 Chromatin signaling and epigenetics; 1.2 Chromatin organization; 1.3 Histone posttranslational modifications and the histone code; 1.4 Functions of histone posttranslational modifications; 1.5 DNA methylation; 1.6 Writers, erasers, and readers; 1.6.1 Histone writers
- 1.6.2 DNA writers1.6.3 Histone erasers; 1.6.4 DNA erasers; 1.6.5 Histone readers; 1.6.6 DNA readers; 1.7 Modification cross talk; 1.8 Effects of metabolism on histone and DNA modifications; 1.9 Epigenetic inheritance; 1.10 Summary; References; 1
- Neurodegenerative disorders; 2
- Into the unknown: chromatin signaling in spinal muscular atrophy; 2.1 Spinal muscular atrophy: prevalence, genetic basis, clinical features, and pathogenesis; 2.2 The survival motor neuron protein: localization, structure, and function; 2.3 Epigenetic landscape in spinal muscular atrophy pathogenesis
- 2.4 Targeting epigenetic factors as potential therapeutics in spinal muscular atrophy2.4.1 Histone deacetylase inhibitors as regulators of the survival motor neuron gene; 2.4.2 The nonspecific effect of histone deacetylase inhibitors; 2.4.3 The potential protective effect of histone deacetylase inhibitors in the pathogenesis of spinal muscular atrophy; 2.5 Conclusion; Acronyms and abbreviations; Acknowledgments; References; 3
- Charcot-Marie-Tooth disease; 3.1 Introduction; 3.2 Epigenetic regulation of Schwann cell development; 3.3 Epigenetic regulation of dosage-sensitive genes
- 3.4 Epigenetic regulators targeted by CMT mutations3.4.1 DNMT1; 3.4.2 LMNA; 3.4.3 SYNE1; 3.4.4 MED25; 3.4.5 SETX; 3.4.6 MORC2; 3.4.7 PRDM12; 3.5 Novel mechanisms for CMT mutations; 3.6 Summary; Acknowledgments; References; 4
- Epigenetic mechanisms in Huntington's disease; 4.1 Introduction; 4.2 Huntington's disease; 4.2.1 Neuropathology of HD; 4.3 Transcriptional dysregulation in HD; 4.4 Altered epigenetic marks in HD; 4.4.1 Histone modifications; 4.4.1.1 Histone acetylation; 4.4.1.2 Histone acetylation alterations in HD; 4.4.1.3 Histone methylation; 4.4.1.4 Histone methylation changes in HD
- 4.4.1.5 Histone phosphorylation4.4.1.6 Histone phosphorylation and HD; 4.4.1.7 Histone ubiquitination; 4.4.1.8 Altered histone ubiquitination in HD; 4.4.2 DNA methylation; 4.4.3 DNA methylation changes in HD; 4.4.3.1 Global DNA methylation changes; 4.4.3.2 Gene-specific DNA methylation changes; 4.4.3.3 Implicating DNA methylation enzymes; 4.5 Epigenetic-based therapies; 4.5.1 HDAC inhibitors as a treatment for HD; 4.5.2 Methylation-inhibiting drugs; 4.6 Concluding remarks; 4.7 Abbreviations; References; 5
- The epigenetics of multiple sclerosis